18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.

Nicolas Aide; Kathryn Kinross; Carleen Cullinane; Peter Roselt; Kelly Waldeck; Oliver Neels; Donna Dorow; Grant McArthur; Rodney J Hicks

doi:10.2967/jnumed.109.073288

18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.

Identifier:nobleid.org/w1/20260515/AB8CDFEA

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/AB8CDFEA.svg?ark=w1%2F20260515%2FAB8CDFEA)](https://nobleid.org/work/w1/20260515/AB8CDFEA)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.

Identifier:nobleid.org/w1/20260515/AB8CDFEA

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/AB8CDFEA.svg?ark=w1%2F20260515%2FAB8CDFEA)](https://nobleid.org/work/w1/20260515/AB8CDFEA)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work